The Inside Scoop on Creative Medical Technology Holdings Inc (OTCMKTS: CELZ)

0

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) has been on the move in recent days since reversing off $0.01 lows. CELZ s a really exciting Company that has attracted legions of shareholders who see big things happening here.

The stock is a runner that exploded last year to highs of $0.07 from a start in double zero land.  CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. Creative Medical is a commercial-stage biotechnology company focused on Urology and Neurology using stem cell treatments. The company’s team consists of leading international researchers in regenerative medicine with a “science-first” approach to treatments ensuring that all of its treatments are proven to be both safe and effective.

CELZ is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED.

Creative Medical is currently in the commercial stage of its bone marrow based stem cell treatment for Erectile Dysfunction known as CAVERSTEM, which is being marketed both nationally, and internationally. Earlier this year the Company formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.

CaverStem™ received positive reception at international urology conference. Dr. Alexander Gershman stated “I am very impressed by the strong endorsement we have been receiving from colleagues attending the American Urological Association conference.  Since beginning to offer the CaverStem™ procedure in December 2017 we have treated multiple patients of which approximately 90% have reported positive improvements.  These are all patients for which pharmacological interventions such as Viagra and Cialis do not work. rWhenever a new procedure is introduced to the community, it is fundamentally important to obtain the support of our peers, and to share our findings with our peers.  We are enthusiastic by the interest in CaverStem™ by the American and International Urology Community.”

To Find out the inside Scoop on CELZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Creative Medical is currently marketing CaverStem™ to physicians across the United States. There are currently 14 locations at various stages of development, training marketing, recruiting and treating patients. The Company is currently recruiting additional marketing representatives to gain increase our exposure to physicians. The primary training involves use of the CRM for patient recruitment, interaction between the physician and the patient and patient retention. All in HIPAA compliance. The responses to the benefits of this platform and its ease of use has been positive. Training of other physicians is ongoing.

Internationally Creative Medical successfully sponsored the treatment of two patients in Moscow by Dr. Dmitri Pushkar, Urology General of Russia using the CaverStem™ procedure. The Company is also progressing with the CaverStem™ program in Switzerland and expect to release more information on the treatment of patients in this region soon. Interest in the CaverStem™ procedure remains strong in other EU countries.

The LA Biomedical Institute clinical trial is progressing and it the Company/s intent to disclose the data via a joint publication with LA Bio Med as contractually agreed upon as well as submission to clinicaltrials.gov. The CaverStem™ team members involved in this aspect of the business are working with LA Bio Med to bring this to fruition.

Creative Medical is progressing with the development of the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient’s own bone marrow. Following the same model as CaverStem™, The Company anticipates launching this program in Q1 2019.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $12.5 million market valuation CELZ is fully reporting OTCBB, has $100k in the treasury, little revenues and $10 million in current liabilities. CELZ is a really exciting Company developing in small caps; The stock is a runner that exploded last year to highs of $0.07 from a start in double zero land. and CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CELZ.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.